

BLOOD COMPONENTS AND BLOOD PRODUCTS COLLECTION & ADMINISTRATION

Applicable to: MidCentral Health	Issued by: Hospital Transfusion Committee		
	Contact: Blood Bank /Transfusion Medicine		

PURPOSE

To promote safe taking of pre transfusion blood samples and administration of blood components and products. To facilitate early recognition and treatment of transfusion-related reactions and events. To record and report any suspected adverse transfusion reaction to Blood Bank, New Zealand Blood Service (NZBS).

SCOPE

Applies to all Registered & Enrolled nurses, Midwives, Anaesthetic Technicians and Medical practitioner's within MidCentral Health.

Blood Bank hours: Monday to Sunday 08:00 to 24:00hours Statutory Holidays 08:00 to 24.00 hours Out of Hours contact via the hospital operator - for Emergency work only.

Consent

- Obtain patient's written informed consent for any blood or blood related product, document on the Operation Procedure Consent Form (Section B).
- Provide the relevant NZBS brochure "Your Guide to Blood Transfusion" to the patients who require this treatment as part of the Informed Consent process. These are available in the resource website in a many languages, or if the patient has an intellectual disability
- Check for known allergies, and previous transfusion reactions.
- N.B. For the ongoing management of a particular disease or disorder, ensure the consent is valid until the treatment or condition or dose changes.

Prescribing

• Authorisation for products other than red cell components is needed:

A Transfusion Medicine Specialist (TMS) or a Haematologist is responsible for authorising platelets, cryoprecipitate, Factor Concentrates, Prothrombinex, Intragam P, Evogam or Zoster Immunoglobulin.

N.B. Requests of >1 bag of platelets and >3 units of cryoprecipitate should be authorized by a TMS or a haematologist.

An Oncologist, ICU consultant or Anaesthetist can request: a unit of platelets; and up to 3 units of cryoprecipitate, or 1 adult dose equivalent to 1 unit / 30Kg bodyweight without this being approved by a haematologist.

- A haematologist or any consultant is responsible for authorising frozen plasma components.
- A midwife may authorise Anti-D Ig, Rhophylac or HIG100 International Units.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 1 of 26

Version: 10 Issue Date: 2022



• A registered Nurse with prescribing rights can prescribe blood components for patients using standing orders.

Pre Transfusion Sample:

- Obtain a group and screen (G&S) blood sample with hand written patient details on the 6ml EDTA pink top blood sample tube and send to Blood Bank.
- Complete all sections of the NZBS Blood Bank Request Form. Ensuring the information on the sample & the form match.
- Label at the patients side.
- Ask open ended questions.
- Confirm patient's family name, given name, NHI AND DOB.
- Check the information against the patient's wristband
- Label the form and Sample immediately, **before leaving the patient**. (*NB: The patients address is not required on a group and screen sample*
- Check all details match. Date and sign the sample and form.

NB: ANY ERRORS WILL NOT BE ACCEPTED BY BLOOD BANK; YOU WILL BE ASKED TO TAKE ANOTHER BLOOD SAMPLE

Pre – Transfusion

- When the Registered Nurse/Midwife/Anaesthetic Technician(AT) is requested to give a transfusion, they must check via Eclair/Clinical portal that there are units available for the patient. If no units available contact blood bank.
- It is the responsibility of the requesting Registered Nurse/Midwife/AT to book an Orderly for blood collection.
- Explain the procedure and prior to ordering blood components ensure informed consent is obtained (Informed Consent [Policy] MDHB-1998) and documented on the operation/procedure consent form section B.
- Ensure the patient is wearing an identification wristband.
- Ensure once the blood component/product is prescribed it is administered promptly, without delaying treatment.
- Ensure that the peripheral IV cannula is patent prior to requesting the blood component.
- Prime the administration set and in-line blood filter with the blood component / Product or 100ml 0.9% Sodium Chloride
- Record the patient's **baseline** temperature, pulse, respiratory rate and blood pressure, O2 Saturation prior to ordering the blood component.
- Enter the following details on the Blood Transfusion Record form and attach a patient's addressograph label to the form [MDHB-4344].
- Arrange for the Orderly to collect the Blood Transfusion Record form [MDHB-4344] via the ward/department and take to Blood Bank to collect the blood products and components.
- Red cells & Fresh Frozen Plasma must be transfused within 4 hours from leaving controlled storage, or **return to Blood Bank within 30 minutes if transfusion is delayed.**

Ensure you check on éclair or the clinical portal your patients products or components are ready for collection.

Page 2 of 26



Blood Collection:

Duty Nurse Manager & Orderlies:

- Duty Nurse Managers can collect blood labelled for an individual patient from the after hour's blood refrigerator.
- Duty Nurse Managers must complete training for afterhours blood uplift provided by Blood Bank.
- Duty Nurse Managers can uplift emergency O negative units from the theatre blood fridge only
- Orderlies will collect the Transfusion Record Form and take to Blood Bank to collect all blood products and components from a transfusion scientist.
- The Orderly must deliver each unit to the requesting Nurse/Midwife/Anaesthetic Technician/Medical Practitioner that will be administering the unit.

Taking Blood from the Theatre Fridge:

- Each unit placed into the blood fridge has a yellow tracking tag attached.
- This tracking tag **MUST** be completed every time a unit is placed into the fridge and removed from the fridge.
- The tracking tag can be completed by any staff handling blood.

Prescribed Blood	Intravenous administration set appropriate
Component	for transfusion
Red cells resuspended	IV Alaris Pump as required
	In-line Filter required for all blood components
Fresh frozen plasma	IV Alaris Pump not required
Platelets	In-line Filter required for all blood components
Cryoprecipitate	
Prescribed Blood Product	No filters required for bottled products
Albumex	IV Administration set
Prothrombinex	Mix2vial system, via Alaris syringe driver or slow
	push
Factor VIII (Biostate®)	Mix2vial system, via syringe.
IV Ig (Intragam P or Privigen®)	IV Alaris pump set.

• Enrolled Nurse under the direct supervision of Registered Nurse/Midwife and Anaesthetic Technician under the direction of an Anaesthetist:

Administration:

- Obtain baseline vital signs and document.
- Requesting a blood component between the hours of Midnight to 0800hrs. Call / page the Duty Nurse Manager to arrange for collection of pre prepared components from the After Hours Blood fridge.
- Ensure a double independent check is performed at the patients' side.
- Administer the blood component or blood related product as prescribed as soon as possible after receipt
- Dispose of the empty blood component bag 24 hours after administration.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 3 of 26

Version: 10 Issue Date: 2022



- If a blood transfusion reaction is suspected *do not* discard blood administration set and unit of blood return to blood bank for investigation.
- Monitor the patient for the response to the transfusion and immediately report all adverse events that occur with the recipient
- Double independent checks are to be performed for blood component/product administration as prescribed
- Monitor the patient closely for any response to the transfusion and immediately report all **Adverse Transfusion Reactions:**

Transfusion Administration:

- Verify the patient's identity, checking against the patients wristband and with the patient if possible, with two IV certified health professionals by way of **double independent checks** at the Patient's side:
- Obtain oral verification from the patient, where possible, by asking for their full name and date of birth.
- When the checks are completed, sign the "Blood Component & Blood Product: Transfusion Record" Form (MDHB-4344) and Medication Chart. Cleanse hands and put on non-sterile gloves.

Equipment

- Intravenous fluid 100ml 0.9% Sodium Chloride for priming line
- 10ml 0.9% Sodium Chloride for Flushing
- 10ml syringe
- Non-sterile gloves
- Alcohol swabs
- Infusion pump if required
- Transfusion Record Blood & Blood Products (MDHB-4344)
- Clamp off the Sodium Chloride 0.9% 100ml bag from administration set and switch on the line with the prescribed blood component.
- Regulate the flow with roller clamp or set the IV pump settings to the prescribed rate.
- Stay with and **observe** the patient during the first **15 minutes** of the transfusion.
- After the **15 minutes** record temperature, pulse, respiratory rate, O2 Saturation and blood pressure.
- If patient exhibits signs of transfusion reaction, follow the New Zealand Blood Service Transfusion-Related Adverse Reaction Notification Form
- If no reaction apparent, continue to record temperature, pulse, respiratory rate and blood pressure again after **30 minutes** and then **hourly**. And again **at the end** of the Transfusion.
- NOTE: this regimen of recording vital signs is a minimum requirement, for a blood transfusion. Your patient may require closer observation.
- **On completion of the transfusion**, flush the line with 0.9% Sodium Chloride. Remove the compatibility/swing label and attach to the blood transfusion record form.
- Ensure the end time is documented on the transfusion record form AND on the prescription.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 4 of 26

Version: 10 Issue Date: 2022



- If more than one unit is being transfused, repeat the above.
- The giving set and filter must be changed every 12 hours or after 10 units. This may need changing sooner.
- Platelets must be transfused through a separate blood filter that has **not** been used previously.

Post Transfusion

If maintenance fluids are prescribed you *must* change the fluid administration set. If no further fluids are to be infused, remove the fluid administration set and flush the vascular access device with 10 - 20 ml 0.9% Sodium Chloride for injection as per MDHB 1019.

- Remove IV cannula, if no longer required.
- Place the empty blood component into the appropriate sealed delivery bag and store in utility room for 24 hours.
 - i. If patient is given blood in the Emergency Department/Operating Theatre send empty bags with the patient on transfer to another ward/department.
 - ii. (NB. If blood transfusion reaction is suspected, do not discard blood administration set with the unit of blood. Return to Blood Bank for investigation as per New Zealand Blood Transfusion-Related Adverse Reaction Notification Form.
- Dispose of equipment into designated containers in the approved manner.
- Update fluid balance chart and the clinical records.

2. ADVERSE TRANSFUSION REACTIONS MANAGEMENT GUIDELINES

Refer to the New Zealand Blood Transfusion-Related Adverse Reaction Notification Form

- All transfusion reactions MUST be reported to Blood Bank. For all moderate to severe transfusion reactions contact the Transfusion Medicine Specialist obtained via blood bank or Clinical Haematologist immediately.
- Refer to NZBlood Service Adverse Transfusion Reaction Management Guideline - (refer to the reverse of the Notification Form (111F009) New Zealand Blood Service Transfusion-Related Adverse Reaction Notification Form
- Return the blood with the administration set attached in the delivery bag to Blood Bank with the completed form 111F009.
- Document all assessments, interventions and patient responses in clinical records.

3. DEFINITIONS

Blood Component – Red cells, platelets, fresh frozen plasma, cryoprecipitate, cryosupernatant.

Page 5 of 26

Version: 10 Issue Date: 2022



Blood Products – Manufactured from human plasma: Albumex, RhD Immunoglobulin, Coagulation Factors, Privigen, Immunoglobulin's, and Prothrombinex.

4. RELATED MDHB DOCUMENTS

MDHB-1998	Informed Consent -Policy-
MDHB-5609	Blood Transfusion and Monitoring Child Health -Guideline-
MDHB-4344	Transfusion Record - Blood Component and Blood Product 730464 -
	Form-
MDHB- 1019	Flushing Vascular Access Devices -Guideline-
MDHB-5372	Intravenous Immunoglobulin (IVIg) Therapy Children -Clinical
	Guideline-
MDHB-6317 MDHB-5896	Protocol for Patients Receiving Regular Blood Transfusions -Form- Adult Massive Haemorrhage Pathway (MHP) & code crimson protocol
Je 10 Je 90	ficult filasofie filaemotinage factoria (and) a code efficient protocor

RELATED NZBS Documents

111F159	Blood Bank Request Form
111F009	Acute Transfusion Reaction Form

5. REFERENCES

- Australian & New Zealand Society of Blood Transfusion (2021) Guidelines for Administration of Blood Components.
- Infusion Nurses Society (2011) Policies and Procedures for Infusion Nursing (4th Ed).
- Bringing consensus to the use of IVIg in Neurology second edition.
- New Zealand Blood Service, Transfusion Medicine Handbook
- MDHB Blood resource folder: https://www.clinicaldata.nzblood.co.nz/resourcefolder/.

6. FURTHER INFORMATION / ASSISTANCE

Transfusion Medical Specialist (Obtained via blood bank) Clinical Haematologist Blood Bank Scientists Transfusion Nurse Specialist - New Zealand Blood Service Clinical Nurse Specialist Intravenous therapies Clinical Nurse Specialist, Coagulation & Haemostasis

7. APPENDICES

See attached appendices:

Appendix 1	Red Cells Resuspended
Appendix 2	Platelets
Appendix 3	Fresh Frozen Plasma
Appendix 4	Cryoprecipitate
Appendix 5	Factor Concentrates
Appendix 6	Prothrombinex
Appendix 7	Immunoglobulin (Ig)

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee

Page 6 of 26

Version: 10 Issue Date: 2022



Appendix 8	Albumin Solutions
Appendix 9	Emergency Transfusion Pack
Appendix 10	Transfusion via a Blood Warmer
Appendix 11	Blood Bank Request form
Appendix 12	Transfusion Record form
Appendix 13	Acute Transfusion Reaction form
Appendix 14	Massive Haemorrhage Pathway / MTP

BLOOD COMPONENTS



Fresh frozen plasma

Platelets



BLOOD PRODUCTS

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 7 of 26

Version: 10 Issue Date: 2022





Appendix 1

RED CELLS RESUSPENDED (Leucocyte depleted, Plasma Reduced)

USES:	To increase tissue oxygenation when critically reduced by loss of blood or anaemia of other origin.			
STORAGE:	2-6°C in controlled blood refrigerator. <u>NOT</u> to be stored in ward refrigerator. See health and safety section of this document.			
DOSAGE:	Dosage depends on the clinical need of the patient and must be adjusted accordingly. A transfusion of 4-5ml/Kg will increase the circulating haemoglobin by approximately 10g/L.			
INFUSION RATE:	Must be transfused within four hours of leaving controlled storage.			
COMPATIBLE WITH:	0.9% Sodium Chloride.			
ADMINISTRATION:	Administer through:			
	 An IV cannula with a bore wide enough to allow for the viscosity of red cells Resuspended, e.g. 18 or 20 gauge, Or Central Venous Catheter 4French or greater. An administration set plus an in-line 170-200 micron filter An IV pump may be used. Complete infusion within four hours of removal from controlled storage in blood bank. Each unit of blood administered must be treated as a separate transfusion. 			

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 8 of 26

Version: 10 Issue Date: 2022



MONITORING:

Take **baseline** temperature, pulse, respiratory rate, and Blood Pressure (BP) and oxygen saturations. Stay with the patient during first 15 minutes and observe patient. After **15 minutes**, repeat all vital signs.

If no reaction noted – continue to record temperature, pulse, respiratory Rate, BP and oxygen saturations again after **30 minutes** and then **hourly** until transfusion is completed and **repeat at the end of the transfusion.**

If Transfusion-related reaction occurs refer to New Zealand Blood Transfusion-Related Adverse Reaction Notification Form

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 9 of 26

Version: 10 Issue Date: 2022



Appendix 2	PLATELETS			
USES:	 To treat thrombocytopenia caused by: Decreased platelet production Functionally abnormal platelets Massive transfusions of stored blood (dilutional thrombocytopenia). 			
INDICATIONS:	Patient bleeding and platelet count <50 x 10 ⁹ /L or less (depends on clinical situation). Patient not bleeding but platelet count 10 x 10 ⁹ /L or less. Usually not indicated where there is increased platelet destruction.			
PRESENTATION:	Apheresis platelets: Bag containing leucodepleted platelets collected by apheresis from a single donor. Usually 1 bag of these platelets is a normal adult dose. Platelet Pool – leucodepleted: Bag containing leucodepleted platelets harvested from four blood donations. Usually 1 bag of these is a normal adult dose. Platelet Additive Solution (PAS Platelets): the additive solution contains citrate, acetate and glucose which maintain the life of the platelet for at least 5 days by providing energy and stabilising the ph. of the unit.			
DOSE:	One unit equals adult therapeutic dose, as prescribed after consultation with a Haematologist/Transfusion Medical Specialist.			
INFUSION RATE:	Must be completed within 1 hour of leaving controlled storage Transfusion should generally be completed within 30 minutes			
ADMINISTRATION:	Platelets need to be administered via an administration set plus a new in-line 170-200 micron filter.			
CONTRAINDICATIONS:	Immune-mediated platelet destruction without haemorrhage Thrombotic thrombocytopenia purpura. Heparin induced thrombocytopenia (HITS) Drug-induced thrombocytopenia without haemorrhage.			
MONITORING:	Observe for transfusion reaction by close observation during the transfusion and immediately afterwards. Take baseline temperature, pulse, respiratory rate, and Blood Pressure and oxygen saturations. Stay with the patient during first 15 minutes and observe patient. After 15 minutes repeat all vital signs, and again on completion .			

Page 10 of 26

Version: 10 Issue Date: 2022



Appendix 3					
FRESH FROZEN PLASMA					
USES:	To supply coagulation factors:				
	 With massive blood transfusion. When patient's coagulation factors are deficient. During sepsis. 				
PRESENTATION:	Unit volume 180-340ml. A delay of 20 minutes will occur as the plasma takes 20 minutes to thaw. Two units will be issued at a time. FFP consists of male donated plasma only.				
[AB Plasma is compatible with all patient blood groups				
	A Plasma is compatible with Patient groups A and O B Plasma is compatible with patients groups B and O				
	O Plasma is compatible with patients group O only				
STORAGE:	Use immediately or return to Blood Bank for appropriate storage within 30 minutes of being thawed. Blood bank can hold thawed for a further 5 days				
DOSAGE:	As prescribed after consultation with Haematologist/Transfusion Medical Specialist or consultant.				
INFUSION RATE:	As prescribed must be administered within 4 hours of being thawed, and transfused over 15- 20 minutes .				
CONTRAINDICATIONS:	Use with caution in patients with hypersensitivity to plasma protein. Hypervolaemia				
ADVERSE EFFECTS:	Urticarial rash, Allergic reactions, Transfusion related acute lung injury (TRALI), Transfusion associated circulatory Overload (TACO)				
ADMINISTRATION:	Administer via a standard blood administration set plus an in- line 170-200 micron filter. Complete administration within 1 hour of commencement.				
MONITORING:	Observe for transfusion reaction by close observation during the transfusion and immediately afterwards.				
	Take baseline temperature, pulse, and respiratory rate, blood pressure, and oxygen saturations. Stay with the patient during first 15 minutes and observe patient. After 15 minutes repeat all vital signs and again on completion .				

Page 11 of 26



Appendix 4	CRYOPRECIPITATE		
USES:	Treatment of Von Willebrand's disease and patients with low fibrinogen and fibrinogen deficiencies, disseminating intravascular coagulation and situations requiring massive transfusions.		
PRESENTATION:	Contains concentrated Factor VIII and XIII, Von-Willebrand's factor and fibrinogen.		
	Bag containing cryoprecipitate. Requires thawing before use, but thawing is rapid for the small volume involved.		
DOSAGE:	One unit/30 kg of body weight, as prescribed after consultation with Haematologist/Transfusion Medical Specialist. Usually 3 units is given for an adult dose		
INFUSION RATE:	Must be transfused immediately and within four hours of being thawed. Generally transfused within 15/20 minutes .		
ADMINISTRATION:	Administer via a standard blood administration set plus an in- line 170-200 micron blood filter.		
CONTRAINDICATIONS:	Use with caution in patients with hypersensitivity to plasma protein. Hypervolaemia		
MONITORING:	Observe for transfusion reaction by close observation during the transfusion and immediately afterwards. Take baseline temperature, pulse, respiratory rate, and blood pressure and oxygen saturations. Stay with the patient for the duration of the transfusion and repeat all vital signs on completion.		

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 12 of 26

Version: 10 Issue Date: 2022



Appendix 5

FACTOR CONCENTRATES (Blood products)

	USES:	PRESENTATION:	STORAGE:	DOSAGE and INFUSION RATE:		
Biostate®	Treatment of Haemophilia A (Factor VIII deficiency) and Von Willebrand's disease. Treatment and prophylaxis of haemorrhage or surgical bleeds.	CSL brand plasma- derived Factor VIII concentrate, Biostate®. Produced entirely from plasma from female volunteer New Zealand blood donors. <u>Vial sizes:</u> 250, 500 & 1000 International Units.	Below 8ºC. Protect from light.	As prescribed by a Haematologist/Transfusion Medical Specialist. Contact CNS Coagulation & Haemostasis for advice/assistance		
ADMINISTRATION: Use within 3 hours of reconstitution. Draw up reconstituted solution using Mix2Vial system. Administer as either a slow intravenous injection into a peripheral IV cannula/central venous access device or a continuous infusions using a standard administration set. A filter is not required.						

MONITORING: Take baseline temperature, pulse, and respiratory rate, blood pressure, and oxygen saturations. Observe for adverse reaction by close observation during the administration and immediately afterwards.

Other products available: Thrombotrol®-VF

Page 13 of 26

Version: 10 Issue Date: 2022



Appendix 5

FACTOR CONCENTRATES RECOMBINANT (Non- Blood products)

	uses:	Presentation:	Storage:	Dosage and infusion
Kogenate - FS®, (Bayer)	Treatment of Haemophilia A (Factor VIII deficiency)	<u>Vial sizes:</u> 250, 500, 1000, 2000 International Units. <u>Note: the filter is in</u> <u>the butterfly</u> <u>provided in the kit</u> <u>that comes with the</u> <u>product.</u>	Below 8°C. Protect from light.	As recommended by a Haematologist/Transfusi on Medical Specialist. Contact CNS Coagulation & Haemostasis for advice/assistance.
Advate (Baxter) BeneFix®	Treatment of Haemophilia A (Factor VIII deficiency) Treatment of Haemophilia	Vial Sizes: 250, 500,1000, 1500 & 3000 international units Vial Sizes: 250 & 1000 international	Below 8°C. Protect from light. Below 8°C. Protect from	
	B (Factor IX deficiency	units	light.	
RiaSTAP	Section 29 Medication	50ml WFI vial & I gram of human fibrinogen Factor 1	Below 8°C. Bring to room temp for reconstitution	Contact TMS or TNS NZBS Via blood bank

ADMINISTRATION: Use within 3 hours of reconstitution. Reconstitute using devices issued with the factor as per instruction's provided in the packet. Administer as either a slow intravenous injection into a peripheral IV cannula/central venous access device or a continuous infusions using a standard administration set. A filter is not required.

MONITORING: Take baseline temperature, pulse, and respiratory rate, blood pressure, and oxygen saturations. Observe for adverse reaction by close observation during the administration and immediately afterwards.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 14 of 26

Version: 10 Issue Date: 2022



Appendix 6

PROTHROMBINEX

Coagulation factor concentrate. Contains Factors II, IX and X.

USES:	Warfarin Reversal Treatment of Factor IX deficiency, Haemophilia B.
DOSAGE:	As prescribed by a Haematologist/Transfusion Medical Specialist. The recommended dosage is expressed in units of Factor IX/Kg of body weight.
INFUSION RATE:	Refer to Warfarin Reversal Consensus Guidelines (2004), CSL Bioplasma. Infuse at a rate of 3ml/minute, or as tolerated by the patient.
ADMINISTRATION:	Reconstitute using Mix2Vial system. Administer using an Alaris syringe driver or a slow push. Prothrombinex must not be mixed with Sodium chloride 0.9%. A filter is not required.
MONITORING:	Observe for transfusion reaction by close observation during the transfusion and immediately afterwards. Take baseline temperature, pulse, respiratory rate, Blood Pressure and oxygen saturations and again on completion.
1	

 Image: definition of the sector of the se

Version: 10 Issue Date: 2022

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 15 of 26



Appendix 7

IMMUNOGLOBULIN (Ig)

INTRAMUSCULAR PREPARATIONS

Normal human immunoglobulins. RhD Immunoglobulin. Specific immunoglobulins, e.g. Tetanus, Zoster, Hepatitis B.

USES: Normal Human Immunoglobulin: little medical application.

RhD Immunoglobulin: prevention of Rh immunisation of Rh Negative mothers after delivery of Rh positive baby or after miscarriage. Administer within 72 hours. Mother must be observed for 20 minutes following administration. Specific Immunoglobulins: as indicated.

ADMINISTRATION: Available as IM preparations.

Refer to package insert for specific information regarding administration, side effects, contraindications, monitoring. Patients must be observed for 20 minutes post administration.

INTRAVENOUS PREPARATION (for Adults) (Paediatrics please refer to MDHB-5372):

Normal human Immunoglobulin in IV preparation.

USES: Treatment of Idiopathic thrombocytopenic purpura (ITP). Guillain Barre Syndrome, Immune deficiency. Intravenous Immunoglobulin's.

New Zealand Blood Service is now a provider of two IV immunoglobulin. For clinical data see <u>https://www.clinicaldata.nzblood.co.nz/resourcefolder/index.php?dhbid=4</u>

The process of requesting these products are:

- Ensure blood bank has a blood group on your patient.
- Ensure you have an accurate weight in your patient.
- Complete the NZBlood "Approval for Immunoglobulin" form.
- When completed send to blood bank.
- Once approval has been given and the IVIg has been selected. Blood bank will inform you of the medication selected for prescription and for requesting.
- Send the "Blood Bank Request form to blood bank, requesting the selected product.
- It will be issued once blood bank receives the Transfusion record form.

Page 16 of 26

Version: 10 Issue Date: 2022



PRESENTATION:	Intragam P 12g in 200mL & 3g in 50mL
	Privigen 5g in 50mL, 10g in 100mL & 20g in 200mL
	 stored in controlled storage
	NB. Each Bottle must be infused within 4 hours of spiking
DOSAGE:	As prescribed by a Neurologist/Haematologist and authorised by Transfusion Medical Specialist

INTRAGAM P INFUSION RATE:

Intragam P is started at 1ml/min (rate 60ml/hour) for 15 minutes. If the patient's observations are stable increase rate by 1ml/minute every 15 minutes until rate is 240 ml/hour.

Rates:		
Times	Rate	Amount infused
		Over 15 minutes
First 15 minutes	60 mL/hour	15 mL
Over next 15 minutes.	120 mL/hour	30 mL
Until finished	180 mL/hour	45 mL
	240 mL/hour	60 mL

NB: Maximum rate 240 ml/hour. Do not increase rate if observations are not stable, remain at slower rate as tolerated by recipient.

MONITORING:

Suitable IVIg monitoring schedule- e.g. Intragam P observation, are as follows:

- TPR/BP every 15 minutes, twice in the second hour, hourly for remainder of infusion
- There is no need to repeat these observations for each bottle.

PRIVIGEN® INFUSION RATE:

- Privigen contains no preservatives to prevent bacterial growth so each bottle should be infused within 4 hours of spiking
- The first infusion should be administered at an initial rate of 0.3 mL/kg/hour.
- If the infusion is well tolerated, the rate can be doubled at 30 min intervals to a maximum rate of 2.4mL/kg/hour, at the discretion of the healthcare professional and as tolerated by the patient.

Page 17 of 26

Version: 10 Issue Date: 2022



First three infusions:

Dosing Schedule	mL/kg/hour
First 30 minutes	0.3mL/kg/hour
Next 30 minutes	0.6mL/kg/hour
Next 30 minutes	1.2mL/kg/hour
Next 30 minutes	2.4mL/kg/hour
Remainder of Infusion	2.4mL/kg/hour

Infusion four onwards:

Dosing Schedule	mL/kg/hour
First 30 minutes	0.3mL/kg/hour
Next 30 minutes	0.6mL/kg/hour
Next 30 minutes	1.2mL/kg/hour
Next 30 minutes	2.4mL/kg/hour
Remainder of Infusion – At the discretion of the healthcare provider	4.8mL/kg/hour

Check the administration rate using calculator available on:

INCOMPATIBILITIES:	https://www.clinicaldata.nzblood.co.nz/resourcefolder/privige n.php?dhbid=4 Drugs or other additives must not be added to the bottle/line.
ADMINISTRATION:	Use an IV pump set and administer via an infusion pump. A filter is not required. When administering multiple bottles, if the batch number is the same then subsequent bottles do not need to be commencing at the slower rate, they can continue at the 240mL/hour.
MONITORING:	 Take baseline observations; temperature, pulse, respiratory rate, blood pressure (BP) and oxygen saturations. Take 15-minute observations (temperature, pulse, respiratory rate and BP) for the first hour then hourly or when changing each bottle. Monitor Patient for 20 minutes post infusion.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 18 of 26

Version: 10 Issue Date: 2022



Appendix 8	
	ALBUMIN SOLUTIONS
USES:	Albumex 20%: Hypoproteinaemia, Burns Albumex 4%: Hypovolaemic shock, Plasma exchange, Haemodialysis
PRESENTATION:	1. <u>Albumex 4%</u> Contains 4g Albumin in 100 ml of buffered solution or 2g Albumin in 50ml in buffered solution (Na contents 140mmol/l).
	2. <u>Albumex 20%</u> Normal serum albumin (human) concentrated. Contains 20g of Albumin in 100ml of buffered solution (Na contents 85-130mmol/l). Osmotically equivalent to 500ml of human plasma.
STORAGE:	2-8°C in a controlled storage refrigerator, use promptly once issued for a patient or return to Blood Bank.
	Do not freeze. Protect from light.
DOSAGE:	As prescribed, use immediately when opened.
INFUSION RATE:	1. Albumex (4%) - not exceeding 6 hours. 2. Albumex (20%) - over 30-60 minutes.
INCOMPATIBILITIES:	Drugs or other additives must not be added to the bottle/line.
CONTRAINDICATIONS:	See package insert.
ADMINISTRATION:	 Inspect the contents immediately before use: Do not use if any sign of turbity (cloudiness). Insert a filtered air inlet needle into bottle when not using a vented administration set. (A 170-200 micron in-line filter is not required.) Use immediately on opening. Discard unused solutions.
MONITORING:	Monitor for signs of circulatory overload particularly with Albumex 20%. Monitor blood pressure and pulse hourly. Monitor other vital signs as indicated by patient's condition.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 19 of 26

Version: 10 Issue Date: 2022



Appendix 9

EMERGENCY TRANSFUSION PACK

Advise Blood Bank that the Emergency O Negative units have been used, so that they can be replaced.

 USES: Immediate resuscitation of exsanguinating patients, wherrisk of delaying transfusion is greater than the risk of transfusing incompatible blood. PRESENTATION: 4 units of group O red cells resuspended, each with a blan Compatibility label attached stamped "CROSSMATCH NC COMPLETE AT TIME OF ISSUE", in a blood box. Arrang collection by an Orderly. STORAGE: 4 units O negative in PACU/Operating Theatre. Do store in the boxes provided while in the blood fridge. Once removed from the blood fridge place unit into box provide keep lid of blood box closed as much as possible. DOSAGE: As prescribed by senior medical practitioner responsible f management of the patient. INFUSION RATE: As prescribed. COMPATIBLE WITH: As for red cells resuspended. Note: These units MAY NOT be compatible with the interrecipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. ADMINISTRATION: As for red cells resuspended Note: Document the transfusion as usual, using the supp blank compatibility labels. 	ISSUED:	4 units O Negative units readily accessible in theatre . Blood Bank MUST be informed of their use immediately. 2 further emergency packs available upon request to blood bank.
PRESENTATION:4 units of group O red cells resuspended, each with a blan Compatibility label attached stamped "CROSSMATCH NG COMPLETE AT TIME OF ISSUE", in a blood box. Arrang collection by an Orderly.STORAGE:4 units O negative in PACU/Operating Theatre. Do store in the boxes provided while in the blood fridge. Once removed from the blood fridge place unit into box provide keep lid of blood box closed as much as possible.DOSAGE:As prescribed by senior medical practitioner responsible f management of the patient.INFUSION RATE:As for red cells resuspended.Note:These units MAY NOT be compatible with the inter recipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue 	USES:	Immediate resuscitation of exsanguinating patients, where the risk of delaying transfusion is greater than the risk of transfusing incompatible blood.
STORAGE:4 units O negative in PACU/Operating Theatre. Do store in the boxes provided while in the blood fridge. Once removed from the blood box closed as much as possible.DOSAGE:As prescribed by senior medical practitioner responsible f management of the patient.INFUSION RATE:As prescribed.COMPATIBLE WITH:As for red cells resuspended.Note:These units MAY NOT be compatible with the inter recipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. 	PRESENTATION:	4 units of group O red cells resuspended, each with a blank Compatibility label attached stamped "CROSSMATCH NOT COMPLETE AT TIME OF ISSUE", in a blood box. Arrange collection by an Orderly.
DOSAGE:As prescribed by senior medical practitioner responsible f management of the patient.INFUSION RATE:As prescribed.COMPATIBLE WITH:As for red cells resuspended.Note:These units MAY NOT be compatible with the inter recipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusi Pack should only be undertaken when the risk of th incompatibility is deemed to be lower than the risk delaying transfusion until compatible blood is avaiADMINISTRATION:As for red cells resuspended Note: Document the transfusion as usual, using the supp 	STORAGE:	4 units O negative in PACU/Operating Theatre. Do not store in the boxes provided while in the blood fridge. Once removed from the blood fridge place unit into box provided and keep lid of blood box closed as much as possible.
 INFUSION RATE: As prescribed. COMPATIBLE WITH: As for red cells resuspended. Note: These units MAY NOT be compatible with the interrecipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusi Pack should only be undertaken when the risk of th incompatibility is deemed to be lower than the risk delaying transfusion until compatible blood is avai ADMINISTRATION: As for red cells resuspended Note: Document the transfusion as usual, using the supp blank compatibility labels. 	DOSAGE:	As prescribed by senior medical practitioner responsible for management of the patient.
 COMPATIBLE WITH: As for red cells resuspended. Note: These units MAY NOT be compatible with the interrecipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusi Pack should only be undertaken when the risk of th incompatibility is deemed to be lower than the risk delaying transfusion until compatible blood is avai ADMINISTRATION: As for red cells resuspended Note: Document the transfusion as usual, using the supp blank compatibility labels. 	INFUSION RATE:	As prescribed.
 Note: These units MAY NOT be compatible with the interrecipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issue a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusi Pack should only be undertaken when the risk of th incompatibility is deemed to be lower than the risk delaying transfusion until compatible blood is avai ADMINISTRATION: As for red cells resuspended Note: Document the transfusion as usual, using the supp blank compatibility labels. 	COMPATIBLE WITH:	As for red cells resuspended.
ADMINISTRATION:As for red cells resuspendedNote:Document the transfusion as usual, using the supp blank compatibility labels.MONITORING:As for red cells resuspended.		Note: These units MAY NOT be compatible with the intended recipient, particularly if the recipient has red cell antibodies. The Emergency Transfusion Pack issued for a male patient may contain Rh (D) Positive blood. Transfusion of units from the emergency Transfusion Pack should only be undertaken when the risk of this incompatibility is deemed to be lower than the risk of delaying transfusion until compatible blood is available.
Note: Document the transfusion as usual, using the supp blank compatibility labels.MONITORING:As for red cells resuspended.	ADMINISTRATION:	As for red cells resuspended
MONITORING: As for red cells resuspended.		Note: Document the transfusion as usual, using the supplied blank compatibility labels.
	MONITORING:	As for red cells resuspended.

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 20 of 26

Version: 10 Issue Date: 2022



Appendix 10

Transfusions via a Blood Warmer

Indications

- Large volume rapid transfusions of >50 mL/kg/hour in adults and >15 mL/kg/hour in children.
- Exchange transfusion in infants.
- Patients with clinically significant cold agglutinins. Blood Bank will advise.
- Note: Blood must not be warmed above 41 °C. Rapid infusion of cold blood can cause arrhythmias and cardiac arrest.

If Blood Warmer is required, obtain blood warmer device and consumables from Post Anaesthetic Care Unit in Operating Theatre and instructions on how to use the blood warmer.

Blood Warmers are held in the following areas: Emergency Department, Intensive Care Unit and Operating Theatre.

General Recommendations:

- The operating temperature of the commercial blood warmer must be recorded on the patients' infusion record when used to warm red cells.
- Blood administration sets used with a warmer must be primed as with other blood administration sets prior to use.
- Improvised warming such as putting the pack in hot water, in a microwave oven, or on a radiator must NEVER be used. These methods may damage red cells and cause harm to the patient.
- All blood components can be put through a blood warmer

Page 21 of 26

Version: 10 Issue Date: 2022



Family	nt:															
	Name										Place	of Surg	ery / Tran	sfusion	n	
Given	Names										Date	of Surge	ry / Trans	fusion		
н			Date of Birt	th			Ge	ender				ou ge	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
patie	nt is a n	eonate	Family Nam	e			NF	41			Ward	/ Hospit	al			
othe	r's detai	is:	Given Name	15			Da	te of Birt	1		1					
iagn	osis / In	dication for tra	nsfusion								Consu	ltant				
listo	rv affe	cts validity	of the bloc	d sample	for the	provi	sion of	red cel	s for tra	nsfus	ion – p	lease	see ove			
ou m	ust com	plete all 3 ques	tions - pleas	etick: Tra	insfused	in the la	st 3 mont	hs?		10100			Unkno	000		
		prete un o ques	picus	Pro	eqnant in	the last	3 months	?	ÖY	85	ON	2	Unkno	wn	0	NA
				Rh	D Ig give	n in the	last 3 mo	nths?	O Y	es	O No		Unkno	nwn		
100	d Bank	Tests: If the	e request i	s urgent p	olease p	phone	the Blo	od Bar	k							
G	roup & A	Intibody Screen		O Cord (Group & D	AT			0	irect Ar	ntiglobuli	n Test			0	Othe
D 1:	st Antena	atal Group & Sc	reen	O Subse	quent Ant	tenatal (Group & S	creen	OA	ntenata	Antiboo	dy Titre				
om	ponen	t Required:					Fr	action	ited Pro	ductl	Require	ed:				
			Number	Date an	nd Time P	Required	±				Dose		Date an	d Time	Requi	red
ed C	alls	Adult					Rh	D Immur	oalobulin		0	25 IU				
		Neonatal									02	250 IU				
atele	ts	Adult					Pr	othrombi	nex-VF							
		Neonatal					IVI	g*	Requires price	approval	_					
P		Adult					All	burnex 4			_					
		Neonatal		_			Al	burnex 20			-					
nyop	recipitati	e		_			He	p. B Imm	unoglobuli	n	-					
uner (Jompon	ents									-					
lequ	ester															
ignat	ure			Print N	ame (if no	t the lab	eller)		Conta	ct No.	/ Pager		Date			
IAN	DATO fy that I irmed ti lled and	Collected the he identity of t signed the si	RATION sample(s) a this patient t ample(s) by	by Perso ccompany by direct er hand imme	ing this r nquiry an ediately a	ecting request id / or i after co	g the S from the nspectio llection a	ample e patient n of the at the be	named al r wristban dside and	bove d I in the	presen	may n	esult in s ne patien	sample t	e rejec	tion
certi conf labe	ctor									ct No.	/ Pager		Time			
certi conf label colle	ctor			Print N	ame (if no	t in the	box abov	e)	Conta	CLINC.	- and a state					
certi conf labei colle ignat landa	ctor ture story			Print N	ame (if no	t in the	box abov	e)	Conta	ci no.	ruger		Date			
certi conf label ignat lands	ctor ture story	t Use: Ix Patient Data Io / Yes / Print	2nd Group No / Yes	Print Na	ame (if no	in the	Regist	e) ered Pr	Conta	ck Fr	ozen /	Authoris	Date	Dat	e	
certii conf label colle ignati and looc	ctor ure story d Bank ed H N ents	t Use: Ix Patient Data Io / Yes / Print	2nd Group No / Yes	Print N	Tx Va	didity	Regist	e) ared Pr	Conta	ck Fr	uzen	Authoris	Date	Dat	e	
certii conf labei colle ignati land: looc eceiv	ctor aure story d Bank ed H N ents	k Use: Ix Patient Data Io / Yes / Print	2nd Group No / Yes Ctrl	Print Na Previous	Tx Va	didity	Registr	e) ered Pr	conta a-test Cheo	ck Fr	ozen i	Authoris	Date	Dat	e C3	Ctr
certi conf abe olle gnat and and ceiv	ctor ture story d Bank ed H N ents	k Use: Ix Patient Data Io / Yes / Print	2nd Group No / Yes Ctrl	Previous A B cells cells	Tx Va	didity	Registr	e) ered Pr	Conta	:k Fr	azen /	Authoris	Date red	Dat IgG	e C3	Ctr

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 22 of 26

Version: 10 Issue Date: 2022



BLOOD COMPONENT & BLOOD PRODUC TRANSFUSION RECORD FORM Orderly to collect this form from the ward/department prior to collecting all blood comport blood products from blood bank. This form can only be sent in the Lamson when requested by a Duty Nurse Manager or the Transfusion Medicine Scientists/Blood Bank Staff. Transfusion Medicine ext 8558 or via the operator out of hours for emergency work only Monday to Friday 08.00 to midnight Saturday and Sunday 09.00 to 17.00 hours	CT:
Orderly to collect this form from the ward/department prior to collecting all blood composition blood products from blood bank. This form can only be sent in the Lamson when requested by a Duty Nurse Manager or the Transfusion Medicine Scientists/Blood Bank Staff. Transfusion Medicine ext 8558 or via the operator out of hours for emergency work only Monday to Friday 08.00 to midnight Saturday and Sunday 09.00 to 17.00 hours	
Transfusion Medicine ext 8558 or via the operator out of hours for emergency work only Monday to Friday 08.00 to midnight Saturday and Sunday 09.00 to 17.00 hours 09.00 to 17.00 hours 09.00 to 17.00 hours	nents & d to do so
emergency work only Saturday and Sunday 09.00 to 17.00 hours	
Statutory holidays 09.00 to 13.00 hours	
"Blood Components and Blood Related Products-Collection and Administration Blood Products and Blood Components must never be stored in ward refrig	gerators
Date: 2 person check at bedside Y/N Informed consent Prescription	
Component / Product required Bload group on unit/label Expire on unit/label	he 1ere
Send to ward/ department Sign Sign Sign Sign Sign Sign Sign Sign	od 111F0 Form
Time issued checked by completed	
Date: 2 person check at bedside Y/N Informed consent Prescription	
Component / Product required Unit number on bog/label Blood group on unit/label Expiry on unit/label	he 1ere
Send to ward/ department Sign administered by Please report any transfusion adverse reactions on NZBIC	xod 111F0
Sign Time Time Transfusion Related Adverse Reaction Notification Time issued checked by completed Image: Checked by completed	FORM

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 23 of 26

Version: 10 Issue Date: 2022



Patient NHI:		DOB:	Male / Fe	male Hospit	al:
Family Name:				Ward:	
Given Names:				Was the anaesth Yes	patient under general esia and/or ventilated? No
Transfusion Details					
Date / time transfusion st	arted:				ed
Date / time transfusion re	action	n detected:		(mL or unit	s)
Donation/unit number(s)	on the	e implicated blood o	component(s):		
Which blood component	(s) we	re administered?			
Red Cells Fresh F	rozen	Plasma Platele	ets Cryopre	cipitate Othe	f *
in the reaction was to a tractic	naiea t	piasma product (e.g. IVIg	g, use the form TTTFO	wavaliable from Bloc	G BUTIK OF WWW.020000.00.02
Clinical History					
Patient's diagnosis and re	eason	for transfusion:			
Will further blood compo	nent s	upport be required i	n the next 24 hou	rs? 🛛 Yes	No Unknown
Patient Vital Signs/Obser	vation	S			
		SpOrt 97	DIA OF	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Baseline (pre starting unit)	RR:	SpO2. /0	O2-Sarl H	R: BP:	Temp: °C
Baseline (pre_starting unit) At time of reaction See ATR management gui	RR: RR: deline:	- $\left \frac{3pO_2}{SpO_2}, \frac{7}{8}\right $	a N/A or H B R/A or H O2	R: BP: R: BP: ilable. Contact via	Temp: <u>•C</u> Temp: •C your local Blood Bank.
Baseline (pre_starting unit) At time of reaction See ATR management gui Mild reaction	RR: RR: deline: Or	- $\frac{3pO_2}{SpO_2}$; $\frac{7}{8}$ s overleaf. Clinical ad Moderci	I <u>O2</u> R/A or R/A or H O2 Sol H Vice is always ava te or severe or	R: BP: R: BP: ilable. Contact via	Temp: <u>°C</u> Temp: °C your local Blood Bank.
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction	RR: RR: deline:	s overleaf. Clinical ad Modera Signs and Symptor	$\begin{bmatrix} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $	R: BP: R: BP: ilable. Contact via life-threatenin pply.	Temp: °C Temp: °C your local Blood Bank.
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from	RR: RR: deline:	s overleaf. Clinical ad Modera Signs and Symptor	$ \begin{array}{c} \begin{array}{c} 0 \\ 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \hline \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $	R: BP: R: BP: ilable. Contact via ilife-threatenin pply. D theorie	Temp: <u>•C</u> Temp: •C your local Blood Bank. Ing reaction
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other	RR: RR: deline:	soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension	C2. Sort H C2. Sort H	R: BP: R: BP: ilable. Contact via life-threatenin pply. Dirachycardia Hypoxia	Temp: •C Temp: •C your local Blood Bank. Ing reaction
At time of reaction At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms	RR: RR: deline:	soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u	C2	R: BP: R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema	Temp: °C Temp: °C your local Blood Bank. Ig reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or	RR: RR: deline:	soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing		R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oec	Temp: •C Temp: •C your local Blood Bank. g reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or	RR: RR: deline:	soverleaf. Clinical ad Moderal Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change		R: BP: liable. Contact via life-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oec e Chest and /or	Temp: •C Temp: •C your local Blood Bank. og reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor Jema Loin Pain
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms	RR: RR: deline:	soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change		R: BP: liable. Contact via life-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oec Chest and /or Abnormal blee	Temp: •C Temp: •C your local Blood Bank. ag reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain iding
At time of reaction At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with no other symptoms Or Localised rash with no other symptoms	RR: RR: deline:	spo2: 78 SpO2: 78 soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea	C2	R: BP: R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oece Chest and /or Abnormal blee Vomiting	Temp: C Temp: C your local Blood Bank. g reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor Jema Loin Pain Inding
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box	RR: RR: deline:	spo2: 7% SpO2: 7% soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other?	C2	R: BP: R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oece Chest and /orl Abnormal blee Vomiting	Temp: •C Temp: •C your local Blood Bank. greaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain ding
At time of reaction At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above	RR: RR: deline:	spo2: 78 SpO2: 76 soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical intervention	C2	R: BP: R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oed Chest and /or Abnormal blee Vomiting o manage reactive	Temp: •C Temp: •C your local Blood Bank. Ig reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain Iding
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms	RR: RR: deline:	spo2: 78 SpO2: 76 soverleaf. Clinical ad Moderal Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical intervention		R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oed Chest and /or Abnormal blee Vomiting o manage reaction	Temp: •C Temp: •C your local Blood Bank. ag reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor Jema Loin Pain Inding
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms are present you <u>must</u> complete the moderale/	RR: RR: Or	SpO2: 78 SpO2: 78 SpO2: 78 SpO2: 78 Soverleaf. Clinical ad Moderal Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical interventio Send Standard ATR TO BLOOD BANK; i	C2	R: BP: Ilable. Contact via Ilife-threatenin pply. Tachycardia Hypoxia Dyspnaea Angioedema Pulmonary acc Chest and /or Angioedema Pulmonary acc Chest and /or Angioedema Or omanage reactions the set of the s	Temp: •C Temp: •C your local Blood Bank. ag reaction Bradycardia Cough Arthythmia Wheeze +/- Stridor dema Loin Pain Iding on?
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms are present you <u>must</u> complete the moderate/ severe reaction section	RR: RR: Or	SpO2: 78 SpO2: 78 soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical intervention Send Standard ATR TO BLOOD BANK: if form. Include a co		R: BP: Ilable. Contact via Ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oec Chest and /or Abnormal blee Vomiting o manage reaction et, hand-labelled post pest form if further tr	Temp: •C Temp: •C your local Blood Bank. g reaction Bradycardia Cough Arthythmia Wheeze +/- Stridor dema Loin Pain Iding on?
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms are present you <u>must</u> complete the moderate/ severe reaction section	RR: RR: deline:	SpO2: 78 SpO2: 78 SpO2: 76 SpO2: 76 Soverleaf. Clinical ad Modera Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical intervention Send Standard ATR TO BLOOD BANK; i form. Include a co TO PATHOLOGY; f		R: BP: R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oece Chest and /orl Abnormal blee Vomiting o manage reaction tet, hand-labelled p pest form if further the UWARD urino	Temp: •C Temp: •C your local Blood Bank. Ig reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain Iding on? Sink top sample & this ansfusion is likely. lysis
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms are present you <u>must</u> complete the moderate/ severe reaction section After medical review: Send this form to Blood	RR: RR: deline:	SpO2: 78 Spo		R: BP: ilable. Contact via ilife-threatenin pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oece Chest and /or Abnormal blee Vomiting o manage reaction et, hand-labelled p yest form if further tr E WARD urina s?	Temp: •C Temp: •C your local Blood Bank. Ig reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain Iding on? which top sample & this ansfusion is likely. Iysis
Baseline (pre starting unit) At time of reaction See ATR management gui Mild reaction I Temperature > 38°C and < 1.5°C from baseline with <u>no</u> other symptoms Or Localised rash with <u>no</u> other symptoms Select only one box above If additional symptoms are present you <u>must</u> complete the moderate/ sever reaction section After medical review: Send this form to Blood Bank. <u>No</u> blood tests are required.	RR: RR: deline:	SpO2: 78 SpO2: 76 soverleaf. Clinical ad Moderal Signs and Symptor Pyrexia/fever Hypertension Restless/Anxiety Extensive rash or u Extensive flushing LOC change Pain at IV site Diarrhoea Other? Clinical intervention Send Standard ATA TO BLOOD BANK: form. Include a ca TO PATHOLOGY: 1 Addition Hoph		R: BP: Iliable. Contact via BF: Iliable. Contact via Ilife-threatenin Pply. Tachycardia Hypoxia Dyspnoea Angioedema Pulmonary oece Chest and /or Abnormal blee Ovomiting o manage reactions to manage reactions to manage reactions of manage reacti	Temp: •C Temp: •C your local Blood Bank. ag reaction Bradycardia Cough Arrhythmia Wheeze +/- Stridor dema Loin Pain Iding on? whick top sample & this ansfusion is likely. lysis

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 24 of 26

Version: 10 Issue Date: 2022



Recogr	nise. Respond. Repor	t.
Asse Check: confirm patie Inspect: visual check of Talk with the Patie Are symptoms LIFE Th OR Wrong Blood	IS SUGGESTIVE OF POTENTIA	abel details appearance comfort g/Circulation? nal Unit?
Severe or Life Threatening Events	INFORM medical staff - seek	PROMPT clinical review
 CALL for urgent medical help and review INITATE Resuscitation: ABC DISCONNECT IV infusion set/unit - do NOT discard/restart MAINTAIN venous access with saline via NEW infusion set ADMINISTER IV fluids/O2 if clinically indicated MONITOR TPR/IB/SpO2/urine output (q5-15 min) TREAT according to clinical status/symptoms, noting: anaphylaxis/severe allergy: use NZRC Anaphylaxis/severe allergy: use NZRC Anaphylaxis Guide septic shock: use DHB Sepsis Guidelines cliculatory overload: diuretics, O2, positive alway pressure TRALI: respiratory support, ask NZBS to start donor review ALET: Is haemorthage a possible cause of the hypotension? Resuscitate with fluids and consider further transfusion INFORM your local clinical haematologist or TINS via Blood Bank ASAP or, contact directly if treatment advice needed 	 Moderate Events All symptoms that are not classified as mild, severe or life threatening Disconnect IV infusion set/unit - do NOT discard set/unit Replace IV infusion set Maintain venous access with saline Treat according to clinical status Do NOT restart transfusion 	 Mild Events Fever > 38°C and < 1.5°C above baseline with no other symptoms Localised rash with no other symptoms Medical Review If fever - consider antipyresial If localised rash - consider antihistamine Management Consider restarting transfusion at slower rate. Directly observe for first 15 minutes Increase frequency of monitoring what signs (TR/BP/SpO2) thereafter Decument in clinical notes Send NZBS ATR Notification Form (11)F099 to Blood Bank No blood tests required
Vestigations and Reporting DO - 'Standard AIR Investigations' and undertake 'Ada as needed COMPLET - NZBS AIR Notification Form (111F009) SEND - blood unit/IV set, AIR Notification Form and EDTA (and other samples to Pathology RECORD - in clinical notes	itional Investigations' (pink) sample to BB	If symptoms worsen? STOP translusion and manage as per a moderate or severe event

Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Issue Date: 2022



MHP doc to be attached

Document No: MDHB-1029 Prepared by: Transfusion Nurse Specialist NZBS Authorised by: MidCentral Hospital Transfusion Committee Page 26 of 26

Version: 10 Issue Date: 2022